Search hospitals > New Mexico > Las Cruces
Memorial Medical Center - Las Cruces
Claim this profileLas Cruces, New Mexico 88011
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Stomach Cancer
108 reported clinical trials
13 medical researchers
Summary
Memorial Medical Center - Las Cruces is a medical facility located in Las Cruces, New Mexico. This center is recognized for care of Skin Cancer, Breast Cancer, Breast cancer, Lung Cancer, Stomach Cancer and other specialties. Memorial Medical Center - Las Cruces is involved with conducting 108 clinical trials across 274 conditions. There are 13 research doctors associated with this hospital, such as Atul Kumar, Carolyn Y. Muller, Ursa A. Brown-Glaberman, and Neda Hashemi Sadraei.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Atul KumarUniversity of New Mexico Cancer Center5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
38 drugs studied
Carolyn Y. MullerUniversity of New Mexico Cancer Center1 year of reported clinical research
Studies Endometrial Cancer
Studies Skin Cancer
23 reported clinical trials
44 drugs studied
Ursa A. Brown-GlabermanUniversity of New Mexico Cancer Center5 years of reported clinical research
Studies Breast Cancer
Studies Skin Cancer
20 reported clinical trials
45 drugs studied
Neda Hashemi SadraeiUniversity of New Mexico Cancer Center4 years of reported clinical research
Studies Skin Cancer
Studies Bladder Cancer
14 reported clinical trials
40 drugs studied
Clinical Trials running at Memorial Medical Center - Las Cruces
Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Lymphoma
Oral Cancers
Laryngeal Cancer
Oropharyngeal Carcinoma
Skin Cancer
ALK Gene Rearrangement
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Memorial Medical Center - Las Cruces?
Memorial Medical Center - Las Cruces is a medical facility located in Las Cruces, New Mexico. This center is recognized for care of Skin Cancer, Breast Cancer, Breast cancer, Lung Cancer, Stomach Cancer and other specialties. Memorial Medical Center - Las Cruces is involved with conducting 108 clinical trials across 274 conditions. There are 13 research doctors associated with this hospital, such as Atul Kumar, Carolyn Y. Muller, Ursa A. Brown-Glaberman, and Neda Hashemi Sadraei.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.